Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs525.36 M584.47 M603.95 M579.17 M564.36 M583.67 M—Recherche et développement149.07 M189.96 M189.86 M198.51 M193.49 M187.52 M—Résultat d'exploitation386.43 M630.08 M531.46 M409.94 M97.71 M465.85 M-397.68 MTotal des produits hors exploitation53.04 M-4.25 M-18.86 M19.87 M23.44 M24.41 M—Charges d'intérêts, nettes des intérêts capitalisés71.32 M54.48 M58.36 M53.41 M86.44 M66.86 M—Résultat hors exploitation, hors charges d'intérêts-132.6 M-99.4 M-83.96 M-27.83 M-62.27 M-35.79 M—Revenus/dépenses exceptionnels114.33 M40.67 M6.74 M-5.71 M-739 K-6.65 M—Résultat avant impôts439.47 M625.83 M512.6 M429.81 M121.15 M490.26 M1.55 BPart des actionnaires dans le résultat5.02 M11.99 M3.76 M4.16 M5.72 M4.4 M—Impôts80.28 M113.23 M89.39 M88.51 M37.56 M65.39 M152.24 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts-11.7 M-5.62 M-22.73 M-7.62 M-8.39 M-13.11 M—Résultat net avant activités abandonnées359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BActivités abandonnées———————Résultat net359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BBénéfice par action de base (BPA de base)1.662.391.971.540.381.96—Bénéfice par action dilué (BPA dilué)1.622.341.951.520.371.946.36Nombre moyen d'actions de base en circulation215.42 M215 M214.62 M221.81 M222.62 M217.22 M—Nombre d'actions en circulation après dilution220.88 M218.82 M217.03 M224.21 M224.72 M218.88 M—EBITDA527.95 M792.16 M679.18 M562.87 M258.37 M626 M—EBIT322.93 M577.23 M470.79 M357.53 M55.12 M432.25 M—Coût des ventes637.63 M802.99 M762.53 M731.63 M1.01 B790.5 M—Autres coûts des ventes574.47 M733.72 M696.47 M667.42 M952.32 M735.27 M—Amortissements (flux de trésorerie)205.01 M214.93 M208.4 M205.34 M203.27 M193.75 M342.68 M
Qiagen N.V. Common Shares
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer.